Literature DB >> 31815523

Mechanisms for the transition from physiological to pathological cardiac hypertrophy.

Christopher J Oldfield1, Todd A Duhamel2, Naranjan S Dhalla3.   

Abstract

The heart is capable of responding to stressful situations by increasing muscle mass which is broadly defined as cardiac hypertrophy. This phenomenon minimizes ventricular wall stress for the heart undergoing a greater than normal workload. At initial stages, cardiac hypertrophy is associated with normal or enhanced cardiac function and is considered to be adaptive or physiological; however, at later stages, if the stimulus is not removed, it is associated with contractile dysfunction and is termed as, pathological cardiac hypertrophy. It is during physiological cardiac hypertrophy where the function of subcellular organelles, including the sarcolemma, sarcoplasmic reticulum, mitochondria, and myofibrils may be upregulated, while pathological cardiac hypertrophy is associated with downregulation of these subcellular activities. The transition of physiological cardiac hypertrophy to pathological cardiac hypertrophy may be due to the reduction in blood supply to hypertrophied myocardium as a consequence of reduced capillary density. Oxidative stress, inflammatory processes, Ca2+ handling abnormalities, and apoptosis in cardiomyocytes are suggested to play a critical role in the depression of contractile function during the development of pathological hypertrophy.

Entities:  

Year:  2019        PMID: 31815523     DOI: 10.1139/cjpp-2019-0566

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  18 in total

Review 1.  Novel roles of immunometabolism and nonmyocyte metabolism in cardiac remodeling and injury.

Authors:  Alan J Mouton; John E Hall
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-09-02       Impact factor: 3.619

Review 2.  The role of cellular senescence in cardiac disease: basic biology and clinical relevance.

Authors:  Mozhdeh Mehdizadeh; Martin Aguilar; Eric Thorin; Gerardo Ferbeyre; Stanley Nattel
Journal:  Nat Rev Cardiol       Date:  2021-10-19       Impact factor: 32.419

Review 3.  Cardiomyocyte Proliferation from Fetal- to Adult- and from Normal- to Hypertrophy and Failing Hearts.

Authors:  Sanford P Bishop; Jianyi Zhang; Lei Ye
Journal:  Biology (Basel)       Date:  2022-06-08

Review 4.  Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.

Authors:  David Aluja; Sara Delgado-Tomás; Marisol Ruiz-Meana; José A Barrabés; Javier Inserte
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

5.  MicroRNA-214 contributes to Ang II-induced cardiac hypertrophy by targeting SIRT3 to provoke mitochondrial malfunction.

Authors:  Yan-Qing Ding; Yu-Hong Zhang; Jing Lu; Bai Li; Wen-Jing Yu; Zhong-Bao Yue; Yue-Huai Hu; Pan-Xia Wang; Jing-Yan Li; Si-Dong Cai; Jian-Tao Ye; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2020-11-27       Impact factor: 7.169

6.  Connexin 43 hyper-phosphorylation at serine 282 triggers apoptosis in rat cardiomyocytes via activation of mitochondrial apoptotic pathway.

Authors:  Zhi-Ping Fu; Lu-Lin Wu; Jing-Yi Xue; Lan-E Zhang; Chen Li; Hong-Jie You; Da-Li Luo
Journal:  Acta Pharmacol Sin       Date:  2021-12-20       Impact factor: 7.169

7.  Ndufs1 Deficiency Aggravates the Mitochondrial Membrane Potential Dysfunction in Pressure Overload-Induced Myocardial Hypertrophy.

Authors:  Rongjun Zou; Jun Tao; Junxiong Qiu; Wanting Shi; Minghui Zou; Weidan Chen; Wenlei Li; Na Zhou; Shaoli Wang; Li Ma; Xinxin Chen
Journal:  Oxid Med Cell Longev       Date:  2021-03-03       Impact factor: 6.543

8.  Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses.

Authors:  Xiaowen Shi; Bin Zhang; Zhenliang Chu; Bingjiang Han; Xueping Zhang; Ping Huang; Jibo Han
Journal:  Cardiovasc Ther       Date:  2021-07-01       Impact factor: 3.023

9.  Downregulation of miR-26b-5p, miR-204-5p, and miR-497-3p Expression Facilitates Exercise-Induced Physiological Cardiac Hypertrophy by Augmenting Autophagy in Rats.

Authors:  Jie Qi; Xue Luo; Zhichao Ma; Bo Zhang; Shuyan Li; Jun Zhang
Journal:  Front Genet       Date:  2020-02-19       Impact factor: 4.599

Review 10.  tRNA-Derived Small RNAs and Their Potential Roles in Cardiac Hypertrophy.

Authors:  Jun Cao; Douglas B Cowan; Da-Zhi Wang
Journal:  Front Pharmacol       Date:  2020-09-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.